Paul Emery

Summary

Affiliation: University of Leeds
Country: UK

Publications

  1. ncbi Aspects of early arthritis. Biological therapy in early arthritis--overtreatment or the way to go?
    Kei Ikeda
    Academic Unit of Musculoskeletal Disease, Leeds University, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK
    Arthritis Res Ther 9:211. 2007
  2. ncbi A systematic literature review of strategies promoting early referral and reducing delays in the diagnosis and management of inflammatory arthritis
    Edith Villeneuve
    Department of Rheumatology, CHUM, Montreal, Canada
    Postgrad Med J 89:231-40. 2013
  3. ncbi A systematic literature review of strategies promoting early referral and reducing delays in the diagnosis and management of inflammatory arthritis
    Edith Villeneuve
    University of Leeds, Leeds, UK
    Ann Rheum Dis 72:13-22. 2013
  4. ncbi After treat-to-target: can a targeted ultrasound initiative improve RA outcomes?
    Richard J Wakefield
    NIHR LMBRU Director, LIMM Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Teaching Hospitals NHS Trust, Chapel Allerton Hospital, Leeds LS7 4SA, UK
    Postgrad Med J 88:482-6. 2012
  5. ncbi Depression and anxiety in patients with rheumatoid arthritis: prevalence rates based on a comparison of the Depression, Anxiety and Stress Scale (DASS) and the hospital, Anxiety and Depression Scale (HADS)
    Tanya Covic
    School of Psychology, University of Western Sydney, Australia
    BMC Psychiatry 12:6. 2012
  6. ncbi Pressure and pain in systemic sclerosis/scleroderma--an evaluation of a simple intervention (PISCES): randomised controlled trial protocol
    Begonya Alcacer-Pitarch
    Division of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK
    BMC Musculoskelet Disord 13:11. 2012
  7. ncbi Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment
    Paul Emery
    Division of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK
    Rheumatology (Oxford) 51:v22-30. 2012
  8. ncbi Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study
    Paul Emery
    Division of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK
    Ann Rheum Dis 71:989-92. 2012
  9. ncbi The impact of rheumatoid arthritis on foot function in the early stages of disease: a clinical case series
    Deborah E Turner
    Department of Podiatry, University of Huddersfield, Huddersfield, UK
    BMC Musculoskelet Disord 7:102. 2006
  10. ncbi TRPM3 channel stimulated by pregnenolone sulphate in synovial fibroblasts and negatively coupled to hyaluronan
    Coziana Ciurtin
    Institute of Membrane and Systems Biology, Faculty of Biological Sciences, University of Leeds, Leeds, LS2 9JT, UK
    BMC Musculoskelet Disord 11:111. 2010

Detail Information

Publications183 found, 100 shown here

  1. ncbi Aspects of early arthritis. Biological therapy in early arthritis--overtreatment or the way to go?
    Kei Ikeda
    Academic Unit of Musculoskeletal Disease, Leeds University, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK
    Arthritis Res Ther 9:211. 2007
    ....
  2. ncbi A systematic literature review of strategies promoting early referral and reducing delays in the diagnosis and management of inflammatory arthritis
    Edith Villeneuve
    Department of Rheumatology, CHUM, Montreal, Canada
    Postgrad Med J 89:231-40. 2013
    ..Despite the importance of timely management of patients with inflammatory arthritis (IA), delays exist in its diagnosis and treatment...
  3. ncbi A systematic literature review of strategies promoting early referral and reducing delays in the diagnosis and management of inflammatory arthritis
    Edith Villeneuve
    University of Leeds, Leeds, UK
    Ann Rheum Dis 72:13-22. 2013
    ..Despite the importance of timely management of patients with inflammatory arthritis (IA), delays exist in its diagnosis and treatment...
  4. ncbi After treat-to-target: can a targeted ultrasound initiative improve RA outcomes?
    Richard J Wakefield
    NIHR LMBRU Director, LIMM Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Teaching Hospitals NHS Trust, Chapel Allerton Hospital, Leeds LS7 4SA, UK
    Postgrad Med J 88:482-6. 2012
    ..The statement proposes that targeting therapy to PD activity provides superior outcomes compared with treating to clinical targets alone and introduces the rationale for a new randomised trial using targeted ultrasound in RA...
  5. ncbi Depression and anxiety in patients with rheumatoid arthritis: prevalence rates based on a comparison of the Depression, Anxiety and Stress Scale (DASS) and the hospital, Anxiety and Depression Scale (HADS)
    Tanya Covic
    School of Psychology, University of Western Sydney, Australia
    BMC Psychiatry 12:6. 2012
    ....
  6. ncbi Pressure and pain in systemic sclerosis/scleroderma--an evaluation of a simple intervention (PISCES): randomised controlled trial protocol
    Begonya Alcacer-Pitarch
    Division of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK
    BMC Musculoskelet Disord 13:11. 2012
    ..The primary aim of this trial is to evaluate whether foot pain and foot-related health status in people with Systemic Sclerosis can be improved through the provision of a simple pressure-relieving insole...
  7. ncbi Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment
    Paul Emery
    Division of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK
    Rheumatology (Oxford) 51:v22-30. 2012
    ....
  8. ncbi Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study
    Paul Emery
    Division of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK
    Ann Rheum Dis 71:989-92. 2012
    ..Treatment response in VERA and early rheumatoid arthritis (ERA; >4 months to 2 years) with combination etanercept+methotrexate (ETN+MTX) or MTX monotherapy was compared...
  9. ncbi The impact of rheumatoid arthritis on foot function in the early stages of disease: a clinical case series
    Deborah E Turner
    Department of Podiatry, University of Huddersfield, Huddersfield, UK
    BMC Musculoskelet Disord 7:102. 2006
    ..The purpose of this study was to compare clinical disease activity, impairment, disability, and foot function in normal and early rheumatoid arthritis (RA) feet using standardised clinical measures and 3D gait analysis...
  10. ncbi TRPM3 channel stimulated by pregnenolone sulphate in synovial fibroblasts and negatively coupled to hyaluronan
    Coziana Ciurtin
    Institute of Membrane and Systems Biology, Faculty of Biological Sciences, University of Leeds, Leeds, LS2 9JT, UK
    BMC Musculoskelet Disord 11:111. 2010
    ..The objective of this study was to investigate the potential relevance of Transient Receptor Potential Melastatin 3 (TRPM3) channel to fibroblast-like synoviocytes (FLSs) of patients with rheumatoid arthritis...
  11. ncbi Variability in depression prevalence in early rheumatoid arthritis: a comparison of the CES-D and HAD-D Scales
    Tanya Covic
    School of Psychology, University of Western Sydney, Penrith South DC 1797, NSW, Australia
    BMC Musculoskelet Disord 10:18. 2009
    ..e. depression); and (c) identify similar levels of depression...
  12. ncbi Analysis of Fcgamma receptor haplotypes in rheumatoid arthritis: FCGR3A remains a major susceptibility gene at this locus, with an additional contribution from FCGR3B
    Ann W Morgan
    Institute of Molecular Medicine, Epidemiology and Cancer Research, University of Leeds, St James s University Hospital, Beckett Street, Leeds, LS9 7TF, UK
    Arthritis Res Ther 8:R5. 2006
    ..The increased association with an FCGR3A-FCGR3B haplotype suggests that other polymorphic variants within FCGR3A or FCGR3B, or in linkage disequilibrium with this haplotype, may additionally contribute to disease pathogenesis...
  13. ncbi Abatacept in the treatment of rheumatoid arthritis
    Maya H Buch
    Academic Unit of Musculoskeletal Disease, University of Leeds, Chapeltown Road, Leeds, LS7 4SA, UK
    Arthritis Res Ther 10:S5. 2008
    ..This review summarizes the clinical data supporting this line of treatment and considers the safety and efficacy data from phase II and III trials...
  14. ncbi Inhibiting toll-like receptors in inflammatory disease
    Paul Emery
    Academic Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, Leeds LS7 4SA, UK
    Lancet 368:821-2. 2006
  15. ncbi Introduction
    Paul Emery
    Department of Rheumatology, Academic Unit of Musculoskeletal Disease, University of Leeds, Leeds LS7 45A, United Kingdom
    J Clin Rheumatol 11:S37-8. 2005
  16. ncbi Rheumatoid arthritis: International disparities in access to anti-TNF therapy
    Paul Emery
    NIHR Leeds Musculoskeletal Biomedical Research Unit, LTHT, Academic Section of Musculoskeletal Disease, University of Leeds, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK
    Nat Rev Rheumatol 7:197-8. 2011
    ....
  17. ncbi Role of biologics in early arthritis
    P Emery
    Academic Unit of Musculoskeletal Disease, Department of Rheumatology, 1st Floor, Leeds General Infirmary, Great George Street, Leeds LS1 3EX, United Kingdom
    Clin Exp Rheumatol 21:S191-4. 2003
    ..Aggressive treatment by anti-TNF agents as well as combination therapies of disease modifying anti-rheumatic drugs (DMARDs) in patients with very early disease would be a logical approach to be investigated in the future...
  18. ncbi Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis
    Paul Emery
    Academic Unit of Musculoskeletal Disease, Leeds University, Chapel Town Road, Leeds, LS7 4S, UK
    Rheumatol Int 27:793-806. 2007
    ....
  19. ncbi The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy
    Paul Emery
    University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK
    Arthritis Rheum 63:1200-10. 2011
    ..To evaluate the effects of golimumab on radiographic progression in patients with rheumatoid arthritis (RA)...
  20. ncbi Review of health economics modelling in rheumatoid arthritis
    Paul Emery
    Department of Rheumatology, Leeds General Infirmary, Leeds, England
    Pharmacoeconomics 22:55-69. 2004
    ..In doing so, it is hoped that such studies will provide optimal information to facilitate important decisions on resource allocation...
  21. ncbi Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept
    Maya H Buch
    University of Leeds, Leeds, UK
    Arthritis Rheum 57:448-53. 2007
    ..The goal of this study was to determine the efficacy of etanercept in patients who failed to respond to infliximab...
  22. ncbi Treatment of rheumatoid arthritis
    Paul Emery
    Academic Unit of Musculoskeletal Disease, Leeds Teaching Hospitals NHS Trust, Chapel Allerton Hospital, Leeds LS7 4SA
    BMJ 332:152-5. 2006
  23. ncbi Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life
    Paul Emery
    Rheumatology and Rehabilitation Research Unit, University of Leeds, UK
    J Rheumatol 33:681-9. 2006
    ..This study examined the effect of abatacept, a costimulation modulator, on the health-related quality of life (HRQOL) of patients with rheumatoid arthritis (RA)...
  24. ncbi Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Effi
    P Emery
    Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds corrected
    Ann Rheum Dis 69:1629-35. 2010
    ..This phase III study evaluated the efficacy and safety of rituximab plus methotrexate (MTX) in patients with active rheumatoid arthritis (RA) who had an inadequate response to MTX and who were naïve to prior biological treatment...
  25. ncbi Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study
    Paul Emery
    University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, corrected Leeds, UK
    Arthritis Rheum 62:674-82. 2010
    ..To evaluate how continuation of and alterations to initial year 1 combination etanercept-methotrexate (MTX) therapy and MTX monotherapy regimens affect long-term remission and radiographic progression in early, active rheumatoid arthritis...
  26. ncbi The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial
    Paul Emery
    Academic Unit of Musculoskeletal Disease, Chapel Allerton Hospital, Leeds, UK
    Arthritis Rheum 54:1390-400. 2006
    ....
  27. ncbi Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)
    P Emery
    Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds corrected
    Ann Rheum Dis 69:510-6. 2010
    ..Several agents provide treatment for established rheumatoid arthritis (RA), but a crucial therapeutic goal is to delay/prevent progression of undifferentiated arthritis (UA) or very early RA...
  28. ncbi IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
    P Emery
    Leeds Teaching Hospitals Trust, University of Leeds, Leeds, UK
    Ann Rheum Dis 67:1516-23. 2008
    ..The phase III RADIATE study examined the efficacy and safety of tocilizumab, an anti-IL-6 receptor monoclonal antibody in patients with rheumatoid arthritis (RA) refractory to tumour necrosis factor (TNF) antagonist therapy...
  29. ncbi Certolizumab pegol for the treatment of rheumatoid arthritis
    Sarah Horton
    Division of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, 2nd Floor, Chapel Allerton Hospital, Chapeltown Road, Leeds, LS7 4SA, UK
    Expert Opin Biol Ther 12:235-49. 2012
    ..Furthermore, randomised controlled trials (RCTs) of CZP have demonstrated rapid improvements in workplace and home productivity in patients contributing to reducing the significant socioeconomic burden of RA...
  30. ncbi Magnetic resonance imaging: opportunities for rheumatoid arthritis disease assessment and monitoring long-term treatment outcomes
    Paul Emery
    Department of Rheumatology, University of Leeds, Leeds, UK
    Arthritis Res 4:S6-10. 2002
    ..This article reviews the potential uses of magnetic resonance imaging as a tool for the classification, documentation, and clinical monitoring of RA...
  31. ncbi Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response
    P Emery
    Division of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, UK
    Ann Rheum Dis 70:2063-70. 2011
    ..Individualised treatment has the potential to improve the therapeutic outcomes for patients...
  32. ncbi Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis
    Paul Emery
    University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, UK
    Ann Rheum Dis 70:2126-30. 2011
    ..Evaluate relationships between MRI and clinical/laboratory/radiographic findings in rheumatoid arthritis (RA)...
  33. ncbi Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial
    Paul Emery
    Leeds Institute of Molecular Medicine, University of Leeds, Leeds Teaching Hospitals Trust, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, United Kingdom, UK
    Lancet 372:375-82. 2008
    ....
  34. ncbi Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis
    Paul Emery
    Leeds Institute of Molecular Medicine, University of Leeds, Leeds LS7 4SA, UK
    Rheumatology (Oxford) 50:2223-32. 2011
    ..To assess the efficacy and safety profiles of two different rituximab retreatment regimens in patients with RA...
  35. ncbi Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis
    P Emery
    Academic Unit of Musculoskeletal Disease, Leeds University, Leeds LS7 4S, UK
    Rheumatology (Oxford) 47:392-8. 2008
    ..Early diagnosis of patients with rapidly progressing RA enables immediate and intensive intervention (e.g. with biologic therapy) and a greater opportunity to change the course of disease...
  36. ncbi Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-bli
    Paul Emery
    University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, corrected Leeds, UK
    Arthritis Rheum 60:2272-83. 2009
    ..To assess the safety and efficacy of golimumab in methotrexate (MTX)-naive patients with active rheumatoid arthritis (RA)...
  37. ncbi Adalimumab therapy: clinical findings and implications for integration into clinical guidelines for rheumatoid arthritis
    Paul Emery
    Leeds Teaching Hospital Trust, University of Leeds, Leeds, UK
    Drugs Today (Barc) 41:155-63. 2005
    ..However, direct comparisons in controlled, long-term trials are needed to draw conclusions about which agent to try first in the sequence of DMARDs considered for patients...
  38. ncbi The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis
    Paul Emery
    Academic Unit of Musculoskeletal Disease, Department of Rheumatology, 1st Floor, Leeds General Infirmary, Great George Street, Leeds, LS1 3EX
    Expert Opin Investig Drugs 12:673-81. 2003
    ..These results suggest that activated T cells may be important in RA pathogenesis and that costimulation blockade may be a novel therapeutic approach for this disorder...
  39. ncbi Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide
    P Emery
    Department of Rheumatology and Rehabilitation, University of Leeds School of Medicine, Leeds, UK
    Ann Rheum Dis 61:290-7. 2002
    ....
  40. ncbi Evaluation of the rheumatoid arthritis susceptibility loci HLA-DRB1, PTPN22, OLIG3/TNFAIP3, STAT4 and TRAF1/C5 in an inception cohort
    Ann W Morgan
    NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Institute of Molecular Medicine, University of Leeds, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK
    Arthritis Res Ther 12:R57. 2010
    ..This study investigated five confirmed rheumatoid arthritis (RA) susceptibility genes/loci (HLA-DRB1, PTPN22, STAT4, OLIG3/TNFAIP3 and TRAF1/C5) for association with susceptibility and severity in an inception cohort...
  41. ncbi Disease remission state in patients treated with the combination of tumor necrosis factor blockade and methotrexate or with disease-modifying antirheumatic drugs: A clinical and imaging comparative study
    Benazir Saleem
    University of Leeds, Chapel Allerton Hospital, Leeds, UK
    Arthritis Rheum 60:1915-22. 2009
    ..We undertook this study to determine whether the difference in radiographic outcome is a result of more complete suppression of imaging-detected synovitis...
  42. ncbi Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?
    Benazir Saleem
    Leeds Institute of Molecular Medicine, University of Leeds, Chapel Allerton Hospital, Chapeltown Road, Leeds, UK
    Ann Rheum Dis 69:1636-42. 2010
    ..However, there are no guidelines regarding cessation of therapy. There is a need for markers predictive of sustained remission following cessation of TNF blocker therapy...
  43. ncbi C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept
    Maya H Buch
    University of Leeds, Leeds General Infirmary, Great George Street, Leeds LS1 3EX, UK
    Arthritis Rheum 52:42-8. 2005
    ..CRP suppression at week 12 in the NRs was associated with a late clinical improvement with infliximab treatment (24 weeks), whereas failure to suppress the CRP at week 12 was associated with a good response on switching to etanercept...
  44. ncbi Delay in imaging versus clinical response: a rationale for prolonged treatment with anti-tumor necrosis factor medication in early rheumatoid arthritis
    Richard J Wakefield
    Chapel Allerton Hospital, Leeds, UK
    Arthritis Rheum 57:1564-7. 2007
  45. ncbi Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis
    Helena Marzo-Ortega
    Consultant Rheumatologist, Academic Unit of Musculoskeletal Disease, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK
    Ann Rheum Dis 66:778-81. 2007
    ..On MRI, areas of active clinical involvement are represented by bone oedema and synovitis. Aim: To assess the impact of infliximab on bone oedema in PsA as shown by MRI...
  46. ncbi Dissection of the FCGR3A association with RA: increased association in men and with autoantibody positive disease
    James I Robinson
    NIHR Leeds Musculoskeletal Biomedical Research Unit, St James s University Hospital, Leeds Institute of Molecular Medicine, University of Leeds, Leeds LS9 7TF, UK
    Ann Rheum Dis 69:1054-7. 2010
    ..This study aimed to replicate previous candidate gene studies that had identified a significant association between the FCGR3A-158V allele and RA and then sought to estimate specific subgroup effects...
  47. ncbi Can flare be predicted in DMARD treated RA patients in remission, and is it important? A cohort study
    Benazir Saleem
    Divsion of Musculoskeletal Disease, University of Leeds, Leeds, UK
    Ann Rheum Dis 71:1316-21. 2012
    ..This study aimed to determine the clinical, functional and imaging associations of disease flare in patients with RA in remission and any effect on long-term outcomes...
  48. ncbi Should imaging be a component of rheumatoid arthritis remission criteria? A comparison between traditional and modified composite remission scores and imaging assessments
    Benazir Saleem
    Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, Leeds Teaching Hospital NHS Trust, Chapel Allerton Hospital, Leeds, UK
    Ann Rheum Dis 70:792-8. 2011
    ..This hypothesis was examined by studying patients using more stringent thresholds for clinical remission and determining their levels of ultrasound synovitis...
  49. ncbi A multicenter reliability study of extremity-magnetic resonance imaging in the longitudinal evaluation of rheumatoid arthritis
    Philip G Conaghan
    Academic Unit of Musculoskeletal Disease, University of Leeds, Leeds, UK
    J Rheumatol 34:857-8. 2007
    ..Overall, E-MRI demonstrated ability to detect change comparable to that reported for high-field MRI for erosion and synovitis...
  50. ncbi Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-m
    Mark A Quinn
    Academic Unit of Musculoskeletal Disease, First Floor, Leeds General Infirmary, Great George Street, Leeds LS1 3EX, UK
    Arthritis Rheum 52:27-35. 2005
    ..At 2 years, functional and quality of life benefits were sustained, despite withdrawal of infliximab therapy. These data may have significant implications for the optimal use of expensive biologic therapies...
  51. ncbi B cell biomarkers of rituximab responses in systemic lupus erythematosus
    Edward M Vital
    University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals National Health Service Trust, Leeds, UK
    Arthritis Rheum 63:3038-47. 2011
    ....
  52. ncbi Enumeration and phenotypic characterization of synovial fluid multipotential mesenchymal progenitor cells in inflammatory and degenerative arthritis
    Elena A Jones
    University of Leeds, Leeds, UK
    Arthritis Rheum 50:817-27. 2004
    ..These findings could determine the role of MPCs in the pathogenesis of inflammatory arthritis, together with their role in attempted joint regeneration in degenerative arthritis, which has yet to be established...
  53. ncbi A randomized controlled trial of early intervention with intraarticular corticosteroids followed by sulfasalazine versus conservative treatment in early oligoarthritis
    Helena Marzo Ortega
    Chapel Allerton Hospital, Leeds, UK
    Arthritis Rheum 57:154-60. 2007
    ..To determine the outcome after 52 weeks of early intervention with intraarticular corticosteroid injections followed by sulfasalazine versus conservative therapy in patients with recent-onset oligoarthritis in a randomized controlled trial...
  54. ncbi Ten-year follow-up of SpA-related oligoarthritis involving the knee: the presence of psoriasis but not HLA-B27 or baseline MRI bone oedema predicts outcome
    Alexander N Bennett
    Academic Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK
    Rheumatology (Oxford) 51:1099-106. 2012
    ..The aim of this study was to investigate the influence of HLA-B27, MRI BMO and psoriasis on long-term outcomes in early SpA-related knee joint oligoarthritis...
  55. ncbi Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis
    Victoria Bejarano
    University of Leeds, Leeds, UK
    Arthritis Rheum 59:1467-74. 2008
    ..To compare work disability and job loss in early rheumatoid arthritis (RA) patients receiving adalimumab plus methotrexate (adalimumab + MTX) versus MTX alone...
  56. ncbi Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis
    Nick Barkham
    University of Leeds, UK
    Ann Rheum Dis 69:1926-8. 2010
    ..The aim of this study was to determine whether etanercept improves work instability as measured by the Ankylosing Spondylitis Work Instability Scale (AS-WIS)...
  57. ncbi Reevaluation of the interaction between HLA-DRB1 shared epitope alleles, PTPN22, and smoking in determining susceptibility to autoantibody-positive and autoantibody-negative rheumatoid arthritis in a large UK Caucasian population
    Ann W Morgan
    Leeds Musculoskeletal Biomedical Research Unit, Institute of Molecular Medicine, University of Leeds, St James University Hospital, Leeds, UK
    Arthritis Rheum 60:2565-76. 2009
    ..To define interactions between the HLA-DRB1 shared epitope (SE), PTPN22, and smoking in cyclic citrullinated peptide (CCP) antibody- and rheumatoid factor (RF)-positive and -negative rheumatoid arthritis (RA)...
  58. ncbi Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis
    Nick Barkham
    University of Leeds, Leeds, UK
    Arthritis Rheum 60:946-54. 2009
    ..To evaluate the efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging (MRI)-determined early sacroiliitis, using both clinical and MRI assessments...
  59. ncbi Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis
    Shouvik Dass
    University of Leeds, and Leeds Teaching Hospitals National Health Service Trust, Leeds, UK
    Arthritis Rheum 58:2993-9. 2008
    ..A highly sensitive assay was used to test the hypothesis that B cell depletion is variable, and that incomplete depletion leads to a poorer outcome...
  60. ncbi Confirmation of association of FCGR3B but not FCGR3A copy number with susceptibility to autoantibody positive rheumatoid arthritis
    James I Robinson
    NIHR Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK
    Hum Mutat 33:741-9. 2012
    ..Thus, our results may highlight an important role for neutrophils in the pathogenesis of RA, potentially through reduced FcγRIIIb-mediated immune complex clearance...
  61. ncbi Transcriptional profile of native CD271+ multipotential stromal cells: evidence for multiple fates, with prominent osteogenic and Wnt pathway signaling activity
    Sarah M Churchman
    NIHR Leeds Musculoskeletal Biomedical Research Unit and University of Leeds, Leeds, UK
    Arthritis Rheum 64:2632-43. 2012
    ..The aim of this study was to clarify the nature of candidate BM-MSCs by profiling transcripts that reflect different aspects of their putative functions in vivo...
  62. ncbi After treat-to-target: can a targeted ultrasound initiative improve RA outcomes?
    Richard J Wakefield
    Division of Rheumatic and Musculoskeletal Disease, Leeds Institute of Molecular Medicine LIMM, University of Leeds, Leeds, UK
    Ann Rheum Dis 71:799-803. 2012
    ..The statement proposes that targeting therapy to PD activity provides superior outcomes compared with treating to clinical targets alone and introduces the rationale for a new randomised trial using targeted ultrasound in RA...
  63. ncbi Relationship between early bone mineral density changes and long-term function and radiographic progression in rheumatoid arthritis
    Victoria Bejarano
    University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK
    Arthritis Care Res (Hoboken) 64:66-70. 2012
    ....
  64. ncbi Discrepancies in categorizing rheumatoid arthritis patients by DAS-28(ESR) and DAS-28(CRP): can they be reduced?
    Elizabeth M A Hensor
    Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, UK
    Rheumatology (Oxford) 49:1521-9. 2010
    ..The 28-joint disease activity score (DAS-28) guides the use of biologics in RA. The aims of this study were to investigate agreement between the ESR- and CRP-based DAS-28 definitions, and to examine how this agreement may be improved...
  65. ncbi Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis
    Paul Emery
    Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, United Kingdom
    J Rheumatol 36:1429-41. 2009
    ..To determine the relationship between radiographic progression and clinical response for adalimumab plus methotrexate (MTX) versus either monotherapy in patients with early rheumatoid arthritis (RA) in the PREMIER study...
  66. ncbi Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade
    Maya H Buch
    University of Leeds, Leeds, UK
    Arthritis Rheum 50:725-8. 2004
    ..These data do not provide evidence of a dominant role for IL-1 in patients who do not respond to TNF alpha blockade, but they do not exclude a role for other proinflammatory mediators...
  67. ncbi Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial
    Philip G Conaghan
    Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK
    Ann Rheum Dis 70:1968-74. 2011
    ..To evaluate golimumab's effect on MRI-detected inflammation and structural damage in patients with active rheumatoid arthritis (RA) despite methotrexate (MTX)...
  68. ncbi Ankylosing spondylitis, HLA-B27 positivity and the need for biologic therapies
    Jane Freeston
    Academic Department of Musculoskeletal Disease, University of Leeds, Chapel Allerton Hospital, Chapel Allerton, Leeds, UK
    Joint Bone Spine 74:140-3. 2007
    ....
  69. ncbi Response to intramuscular methyl prednisolone in inflammatory hand pain: evidence for a targeted clinical, ultrasonographic and therapeutic approach
    Zunaid Karim
    Academic Unit of Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK
    Ann Rheum Dis 66:690-2. 2007
    ..Hand pain with stiffness is a common clinical presentation to early arthritis clinics, with outcome varying from resolution to the development of rheumatoid arthritis...
  70. ncbi Evidence for a different anatomic basis for joint disease localization in polymyalgia rheumatica in comparison with rheumatoid arthritis
    Helena Marzo Ortega
    University of Leeds, and Chapel Allerton Hospital, Leeds, UK
    Arthritis Rheum 56:3496-501. 2007
    ..This study used contrast-enhanced and fat suppression magnetic resonance imaging (MRI) to evaluate the relationship between synovial and extracapsular inflammation in PMR and early rheumatoid arthritis (RA)...
  71. ncbi Persistently moderate DAS-28 is not benign: loss of function occurs in early RA despite step-up DMARD therapy
    Philip G Conaghan
    Section of Musculoskeletal Disease, Chapel Allerton Hospital, Leeds, UK
    Rheumatology (Oxford) 49:1894-9. 2010
    ..The aim of this study was to examine the effect on patient-reported function of persistently moderate DAS-28 despite modern step-up DMARD therapy in an early arthritis cohort...
  72. ncbi Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients
    Lydia R Coulthard
    NIHR Leeds Musculoskeletal Biomedical Research Unit NIHR LMBRU, University of Leeds, Leeds, UK
    Ann Rheum Dis 70:98-103. 2011
    ..A study was undertaken to investigate whether genetic variation within genes, encoding proteins in the p38 signalling network, contributes to the variable response to TNF antagonists...
  73. ncbi Optimization of a flow cytometry-based protocol for detection and phenotypic characterization of multipotent mesenchymal stromal cells from human bone marrow
    Elena A Jones
    Academic Unit of Musculoskeletal Disease, Leeds Institute for Molecular Medicine, University of Leeds, Leeds, United Kingdom
    Cytometry B Clin Cytom 70:391-9. 2006
    ..The purpose of this work was to verify the phenotype of BM MSCs in vivo and to develop flow cytometry-based methods for their evaluation...
  74. ncbi Distinct topography of erosion and new bone formation in achilles tendon enthesitis: implications for understanding the link between inflammation and bone formation in spondylarthritis
    Dennis McGonagle
    University of Leeds and Chapel Allerton Hospital, Leeds, UK
    Arthritis Rheum 58:2694-9. 2008
    ....
  75. ncbi Regional variation and differential response to therapy for knee synovitis adjacent to the cartilage-pannus junction and suprapatellar pouch in inflammatory arthritis: implications for pathogenesis and treatment
    Laura A Rhodes
    University of Leeds, and Leeds General Infirmary, Leeds, UK
    Arthritis Rheum 50:2428-32. 2004
    ....
  76. ncbi Reducing work disability in Ankylosing Spondylitis: development of a work instability scale for AS
    Gill Gilworth
    Department of Rehabilitation Medicine, Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK
    BMC Musculoskelet Disord 10:68. 2009
    ..The study objective was to explore the concept of Work Instability (a mismatch between an individual's abilities and job demands) in Ankylosing Spondylitis (AS) and develop a Work Instability Scale specific to this population...
  77. ncbi Costimulation blockade in rheumatic diseases: where we are?
    Vincent Goeb
    Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, Leeds LS7 4SA, UK
    Curr Opin Rheumatol 21:244-50. 2009
    ..To describe the mechanisms of action of abatacept (CTLA4-Ig) and summarize the evidence of its efficacy and safety in rheumatoid arthritis (RA) and other rheumatic diseases such as juvenile idiopathic arthritis (JIA)...
  78. ncbi An ultrasonographic study of metatarsophalangeal joint pain: synovitis, structural pathology and their relationship to symptoms and function
    Helen I Keen
    University Department of Medicine and Pharmacology, University of Western Australia, Perth, Australia
    Ann Rheum Dis 70:2140-3. 2011
    ..Pain in the first metatarsophalangeal joint (MTPJ) is common, though the link between pathology and symptoms is poorly understood...
  79. ncbi Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study
    H Marzo-Ortega
    Academic Unit of Musculoskeletal Disease, Department of Rheumatology, 1st Floor, Old Nurses Home, Leeds General Infirmary, Great George Street, Leeds LS1 3EX, UK
    Ann Rheum Dis 64:1568-75. 2005
    ..However, disease flares were reported 8 weeks after the last infusion, indicating that addition of methotrexate failed to extend the infliximab dosing interval...
  80. ncbi FcγRIIIa expression on monocytes in rheumatoid arthritis: role in immune-complex stimulated TNF production and non-response to methotrexate therapy
    Dawn L Cooper
    NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom
    PLoS ONE 7:e28918. 2012
    ..We investigated whether FcγRIIIa/CD16 was upregulated in rheumatoid arthritis (RA), associated with TNF production in response to IC-stimulation, and if this predicted response to methotrexate therapy...
  81. ncbi Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series
    Stephen J Jarrett
    Academic Unit of Musculoskeletal Medicine, University of Leeds, Great George Street, Leeds LS1 3EX, United Kingdom
    J Rheumatol 30:2287-91. 2003
    ..We discuss the literature and potential causal mechanisms, including disease activity, the role of autoantibodies, and shifts in T cell responses...
  82. ncbi Synovial fluid mesenchymal stem cells in health and early osteoarthritis: detection and functional evaluation at the single-cell level
    Elena A Jones
    University of Leeds, Leeds, UK
    Arthritis Rheum 58:1731-40. 2008
    ..This study used the bovine model to explore SF MSCs in health and enumerated them at the earliest stages of human osteoarthritis (OA) in radiographically normal joints...
  83. ncbi Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia
    Frederique Ponchel
    Molecular Medicine Unit, University of Leeds, Leeds, UK
    Arthritis Res Ther 7:R80-92. 2005
    ....
  84. ncbi Elucidation of the relationship between synovitis and bone damage: a randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis
    Philip G Conaghan
    University of Leeds and Leeds General Infirmary, Leeds, UK
    Arthritis Rheum 48:64-71. 2003
    ..In the treatment of patients with RA, outcome measures and therapies should focus on synovitis...
  85. ncbi The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab)
    M H Buch
    Academic Unit of Musculoskeletal Disease, University of Leeds, Leeds, UK
    Rheumatology (Oxford) 47:1469-75. 2008
    ..The study aims were to determine whether pre-treatment synovial cytokine expression predicted infliximab response and whether synovial changes after therapy correlated with response...
  86. ncbi A modification of the Omeract RA MRI score for erosions for use with an extremity MRI system with reduced field of view
    Jane E Freeston
    Academic Unit of Musculoskeletal Disease, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK
    Ann Rheum Dis 66:1669-71. 2007
    ..To develop and test the reliability of a modified version of the OMERACT rheumatoid arthritis magnetic resonance imaging score (RAMRIS) for erosions using extremity MRI (eMRI) with reduced field of view (RAMRIS-RV)...
  87. ncbi Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis
    L C Coates
    Academic Unit of Musculoskeletal Disease, Chapel Allerton Hospital, Chapeltown Road, Leeds, LS7 4SA, UK
    Rheumatology (Oxford) 47:897-900. 2008
    ..To investigate the long-term response to biological therapies in AS in a real life clinical setting and to quantify non-response and response to 'switching' therapies in these cases...
  88. ncbi Imaging of the musculoskeletal system: magnetic resonance imaging, ultrasonography and computed tomography
    Ai Lyn Tan
    Academic Unit of Musculoskeletal Disease, Leeds General Infirmary, Great George Street, Leeds LS1 3EX, UK
    Best Pract Res Clin Rheumatol 17:513-28. 2003
    ..This chapter reviews recent imaging studies relevant to rheumatic diseases...
  89. ncbi Induction of antinuclear antibodies in patients with rheumatoid arthritis treated with infliximab and leflunomide
    Sarah J Bingham
    Leeds General Infirmary, Leeds, UK
    Arthritis Rheum 50:4072-3. 2004
  90. ncbi Does the use of tumour necrosis factor antagonist therapy in poor prognosis, undifferentiated arthritis prevent progression to rheumatoid arthritis?
    B Saleem
    Academic Section of Musculoskeletal Disease, University of Leeds, Leeds, UK
    Ann Rheum Dis 67:1178-80. 2008
    ..To evaluate the ability of tumour necrosis factor (TNF) antagonist therapy to produce remission and prevent progression to rheumatoid arthritis (RA) in patients with poor prognosis undifferentiated inflammatory arthritis (UA)...
  91. ncbi Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study
    S Dass
    Academic Unit of Musculoskeletal Disease, University of Leeds, Leeds, UK
    Ann Rheum Dis 67:1541-4. 2008
    ..Therefore, we performed a double blind, placebo-controlled, randomised pilot study of the efficacy of rituximab in reducing fatigue in pSS...
  92. ncbi Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome
    M A Quinn
    Academic Unit of Musculoskeletal Disease, Department of Rheumatology, Chapel Allerton Hospital, Chapeltown Road, Leeds LS74SA, UK
    Rheumatology (Oxford) 45:478-80. 2006
    ..The aims of this study were to assess the diagnostic and prognostic utility of the second-generation anti-CCP(2) test in a large cohort of early RA patients compared with connective tissue disease (CTD) controls...
  93. ncbi MR imaging of erosions in interphalangeal joint osteoarthritis: is all osteoarthritis erosive?
    A J Grainger
    Department of Radiology, Leeds Teaching Hospitals, Leeds, UK
    Skeletal Radiol 36:737-45. 2007
    ..The aim of this study was to compare routine CR and MRI to investigate erosion numbers and morphology to determine whether hand OA in general is a more erosive disease than previously recognised...
  94. ncbi The impact of escalating conventional therapy in rheumatoid arthritis patients referred for anti-tumour necrosis factor-alpha therapy
    S J Bingham
    Rheumatology Research Unit, First Floor, Old Nurses Home, Leeds General Infirmary, Great George Street, Leeds LS1 3EX, UK
    Rheumatology (Oxford) 43:364-8. 2004
    ..The savings achieved by treating with conventional therapies need to be weighed against the risk of persistent disease activity...
  95. ncbi Abnormal T cell differentiation persists in patients with rheumatoid arthritis in clinical remission and predicts relapse
    C H Burgoyne
    Academic Unit of Musculoskeletal Disease, University of Leeds, Leeds, UK
    Ann Rheum Dis 67:750-7. 2008
    ..Patients with inflammatory and non-inflammatory diseases were used to examine the relationship between inflammation and this T cell subset in vivo...
  96. ncbi Hand bone loss in early undifferentiated arthritis: evaluating bone mineral density loss before the development of rheumatoid arthritis
    G Haugeberg
    Academic Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, UK
    Ann Rheum Dis 65:736-40. 2006
    ..Further studies are needed to evaluate the role of hand bone loss as a prognostic factor and outcome measure in rheumatoid arthritis...
  97. ncbi A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis
    A D Fraser
    Rheumatology and Rehabilitation Research Unit, Old Nurses Home, Great Georges Street, Leeds, West Yorkshire LS1 3EX, UK
    Ann Rheum Dis 64:859-64. 2005
    ..To evaluate the safety and efficacy of adding ciclosporin A (CSA) to the treatment of patients with psoriatic arthritis (PsA) demonstrating an incomplete response to methotrexate (MTX) monotherapy...
  98. ncbi Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment
    E M Vital
    University of Leeds, Chapel Allerton Hospital and Leeds Teaching Hospitals National Health Service Trust, Leeds, UK
    Arthritis Rheum 62:1273-9. 2010
    ..This study was undertaken to examine whether an additional cycle of rituximab would improve B cell depletion and clinical response in patients whose disease did not respond to the initial cycle...
  99. ncbi Fcgamma receptor type IIIA is associated with rheumatoid arthritis in two distinct ethnic groups
    A W Morgan
    University of Leeds, UK
    Arthritis Rheum 43:2328-34. 2000
    ..To investigate a possible association between a functional polymorphism in the intermediate-affinity receptor for IgG called Fc-gamma receptor type IIIA (FcgammaRIIIA [CD16]) and rheumatoid arthritis (RA)...
  100. ncbi Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders
    M H Buch
    Academic Section of Musculoskeletal Disease, Chapel Allerton Hospital, Leeds LS7 4SA, UK
    Rheumatology (Oxford) 46:1153-6. 2007
    ..We followed-up a substantial single-centre cohort to determine kinetics of this secondary loss of response. The licensed dose of 3 mg/kg was used throughout...
  101. ncbi Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience
    L C Coates
    Academic Unit of Musculoskeletal Disease, University of Leeds, Chapel Allerton Hospital, Chapeltown Road, Leeds, UK
    Ann Rheum Dis 67:717-9. 2008
    ..To investigate the response to biologic drugs in psoriatic arthritis and to quantify non-response and outcome from switching agents...